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CASE REPORT Open Access
Cataract and optic disk drusen in a
patient with glycogenosis and di George
syndrome: clinical and molecular report
D. Allegrini1*, S. Penco2ˆ, A. Pece3, A. Autelitano4, G. Montesano4, S. Paci5, C. Montanari5, A. Maver6, B. Peterlin6,
G. Damante7 and L. Rossetti4
Abstract
Background: We report the ophthalmic findings of a patient with type Ia glycogen storage disease (GSD Ia),
DiGeorge syndrome (DGS), cataract and optic nerve head drusen (ONHD).
Case presentation: A 26-year-old white woman, born at term by natural delivery presented with a post-natal
diagnosis of GSD Ia. Genetic testing by array-comparative genomic hybridization (CGH) for DGS was required
because of her low levels of serum calcium. The patient has been followed from birth, attending the day-hospital
every six months at the San Paolo Hospital, Milan, outpatient clinic for metabolic diseases and previously at another
eye center. During the last day-hospital visit, a complete eye examination showed ONHD and cataract in both eyes.
Next Generation Sequencing (NGS) was subsequently done to check for any association between the eye problems
and metabolic aspects.
Conclusions: This is the first description of ocular changes in a patient with GSD Ia and DGS. Mutations explaining
GSD Ia and DGS were found but no specific causative mutation for cataract and ONHD. The metabolic etiology of
her lens changes is known, whereas the pathogenesis of ONHD is not clear. Although the presence of cataract and
ONHD could be a coincidence; the case reported could suggest that hypocalcemia due to DGS could be the
common biochemical pathway.
Keywords: Glycogen storage disease type IA, Hypoglycemic cataract, Hypocalcemic cataract, DiGeorge syndrome,
Optic disk drusen, Microdeletion 22q11.2
Background
We report the clinical and molecular details of a
complex patient presenting cataract and optic disk
drusen with glycogen storage disease (GSD) type Ia and
DiGeorge syndrome (DGS). Type Ia GSD is due to
glucose-6-phosphatase (G6P) deficiency and presents
either at birth with enlarged liver or, more frequently, at
the age of 3–4 months with symptoms of hypoglycemia
induced by fasting (tremors, convulsions, cyanosis and
apnea) [1].
DGS is due to a microdeletion in chromosome
22q11.2, whose common signs include heart disease,
palate anomalies, dysmorphic facial features, develop-
mental delay, immune deficiency and hypocalcemia
associated with hypoparathyroidism.
Case presentation
This case was studied at the San Paolo Hospital, Milan,
Italy, in full respect of the Declaration of Helsinki and
national laws for the protection of personal data; the
patient signed an informed consent form. She is being
followed in the Pediatric Department.
The patient was a 26-year-old Caucasian white
woman, born at term by natural delivery. As a
newborn she had had recurrent episodes of vomiting,
and at four months she was diagnosed with GSD Ia,
by liver biopsy. Genetic testing for G6PC gene
(NM_000151.3) indicated as causative mutations
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c.551G > T (p.Gly184Val) and c.809G > T (p.Gly270-
Val) responsible for GSD Ia (OMIM:232,200).
Over the years, on account of persistent hypocalcemia,
genetic testing for DGS was requested; array-comparative
genomic hybridization (CGH) confirmed the presence of a
2.42 Mb deletion from nucleotide 19.023.824 to
21.44.0514 of the q11.2 region of chromosome 22. Further
analysis indicated that the deletion was inherited from the
mother who also presented hypocalcemia, but none of the
typical ocular signs of DGS. Psychiatric and psychological
evaluations indicated that the patient has an intellectual
disability (Fig. 1).
The patient has been followed from birth, with day-
hospital check-ups every six months at the San Paolo
Hospital, Milan, outpatient clinic for metabolic diseases,
pediatric department. Currently she is under strict diet-
ary control. Her clinical features related to DGS and
GSD Ia are summarized in Table 1. She had previously
also been followed at another eye center which, however,
retains no imaging documentation. The eye check in our
clinic was requested by the day hospital at the hospital’s
center for metabolic diseases.
The patient had Best Corrected Visual Acuity (BCVA)
of 20/25 (+1.00sfere, −2.00 cylinder/60°) in right eye
(OD) and 20/500 (−1.00cylinder/110°) in left eye (OS).
Orthoptic examination found exotropia of 25 prismatic
diopters (PD) in OS, not alternating, with dominance in
OD. The OS was amblyopic, because the patient had
previously refused the use of glasses and occlusion in
OD. Pupils were equal, round and reactive to light,
without restriction or overaction. She had a clear cornea,
deep, quiet anterior chambers and eyelid hooding in
both eyes (OU). Applanation tonometry measured
15 mmHg OU.
In the anterior segment there was: a) a posterior
subcapsular cataract (Fig. 2), which it was manifested at
the age of 18 years in OS more than in OD and it was
gradually increased over the years; b) numerous peripheral
punctate opacities of the lens on 360° (Fig. 3) in OU, not
previously described. We strongly recommended surgical
cataract extraction in OS but the patient refused surgery.
The fundus presented a clear macula, tortuous vessels and
numerous bright yellow ONHD, clearly visible in B scan
ultrasound and autofluorescence HRA-II (Heidelberg
Engineering, Heidelberg, Germany) (Fig. 4). ONHD were
manifested first in OS at age 11 and then in OD at age 13,
increasing in number and size over the years. A computer-
ized visual field examination (Humphrey perimetry) at the
day hospital showed advanced constriction of the OS
greater than OD. It also helped explain the central vi-
sion loss in OU caused by the fixation splitting defect
(Figs. 5, 6) based on the advanced visual field loss in
each eye. We believed that the drusen were the main
cause of the widespread reduction of the visual field;
in fact the lens opacities were not diffuse, but cen-
trally subcapsular and peripherally punctate.
This was confirmed by optical coherence tomography
(OCT HRA-II, Heidelberg Engineering, Heidelberg,
Germany), to further examine the optic nerve. The fast
optic disk scan protocol showed shadowing of the deep
optic nerve consistent with ONHD. The fast retinal
nerve fiber layer thickness scan and analysis indicated
advanced thinning in each eye, which helps depict the
general health of the optic nerve (Fig. 7). The advanced
Fig. 1 Pedigree of the complex case. The index affected case is
indicated by the arrow. Squares represent males; circles, females.
Genetic status of people subjected to genetic test is shown above
the corresponding symbol
Table 1 Clinical features of the patient related with DiGeorge
syndrome and Glycogen Storage Disease Ia
SYSTEMIC CHANGES OCULAR CHANGES
GSD IA hepatomegaly, short
stature, hypotonia
peripheral punctate
opacities of the lens
DGS cleft lip and palate,
dental enamel hypoplasia,
hypoparathyroidism,
intellectual disability
subcapsular cataract, retinal
vascular tortuosity, eyelid
hooding, strabismus,
and astigmatism
Fig. 2 Posterior subcapsular cataract in left eye
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nerve fiber thinning supported the degree of field loss
found on visual field testing.
We checked her parents’ eyes in January 2015. They
were both pseudophakic; the mother and father had
undergone surgery for cataract extraction in OU at the
ages of 60 and 62 years, respectively. They had no
changes in the anterior and posterior segments and in-
traocular pressure and orthoptic findings were normal.
To search for other possible genetic causes of this com-
plex clinical presentation, we applied NGS analysis on
DNA of the proband and her parents. Library preparation
and target selection were done using Illumina Nextera
Coding Exome with subsequent sequencing on an Illu-
mina HiSeq sequencer, in 2 × 100 sequencing mode.
Reads were aligned to UCSC hg19 reference assembly
using the BWA algorithm (v 0.6.3) and variant calling was
done with the GATK framework (v 2.8). Only variants ex-
ceeding the quality score of 30.0 and depth of 5 were used
for downstream analyses. Variant annotation was done
with ANNOVAR and snp Eff algorithms, with pathogen-
icity predictions in the dbNSFPv2 database. Reference
gene models and transcript sequences are based on the
RefSeq database. Structural variants were assessed using
the CONIFER v0.2.2 algorithm. Variants were evaluated
according Meynert AM et al. [2].
Variants for the case were filtered according to de
novo, autosomal recessive and X-linked models of inher-
itance. Taking into account the severity and penetrance
of the sought genetic variation, we filtered out popula-
tion variants attaining frequency above 0.01% in any of
the surveyed populations for de novo model and filtered
out variants exceeding 0.1% in the autosomal recessive
model. All suspect de novo variants were also visually
inspected at aligned read level with the aim of avoiding
false call due to misalignment or low-depth of coverage in
parental samples. Synonymous variants and intronic vari-
ants more than 20 base pairs away form the intron-exon
junctions were disregarded from further interpretation
steps. The genes analyzed are listed in Table 2.
We have utilized two approaches to collect the genes -
we included genes that are associated with Cataract
(HP:0000518) phenotypes, utilizing data collected within
Human Phenotype Ontology database [3]. Additionally,
we supplanted the set of genes with the genes, associated
with cataract in the database of panels, collected in the
EuroGenTest NGS panels database [4].
For DGS the proband’s DNA was analyzed using the
SurePrint G3 human microarray-CGH kit 8x60K
(Agilent). Detailed methods for genomic DNA prepar-
ation, labeling, hybridization and scanning can be found
at websitehttp://www.home.agilent.com.
We identified compound heterozygosity for two
known pathogenic variants associated with GSD Ia
(OMIM:232,200). Whole human exome sequencing did
not show any genetic variants that could adequately
explain the patient’s ocular presentation, focusing on the
genes associated with ocular phenotypes. We did not iden-
tify any plausible candidates gene variants adhering to the
recessive and X-linked models of inheritance. We did iden-
tify one de novo missense variant of unknown significance
Fig. 3 Peripheral opacities of the lens in left eye
Fig. 4 Strong autofluorescence of drusen of optic disk in left eye
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Fig. 5 Computerized visual field: limited area of central sensitivity in right eye
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Fig. 6 Computerized visual field: widespread loss of sensitivity in left eye
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Fig. 7 OCT of the optic nerve: widespread loss of optic nerve fibers in both eyes
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in the USP13 gene (NM_003940.2:c.1544 T > C,
p.Ile515Thr) with conflicting theoretical predictions of
pathogenicity. Furthermore, the USP13 gene itself has
not been associated with the cataract phenotype in
the patient in clinical or functional studies and there
is currently no evidence to support the role of this
variant in the patient’s disease.
However, the analysis used cannot exclude the presence
of pathogenic intronic variants, pathogenic deletions or
duplications, trinucleotide expansions and pathogenic
variants in gene regions that are not captured. Also, it was
not possible to exclude pathogenic variants in genes not
included in the clinical target.
Our results confirmed the previously identified genetic
defects responsible for GSD and DGS, but no specific gen-
etic causes were found for the cataract and/or ONHD.
Discussion
No clear association between GSD Ia and ocular findings
has been reported so far, probably because studies
included only small groups of patients. Fine et al.
described multiple, bilateral, symmetric, yellowish, non-
elevated, discrete paramacular retinal lesions in patients
with GSD Ia, very likely due to specific lipid or glycogen
deposition [5]. Allegrini et al. described multiple,
bilateral, punctate and peripheral opacities of the lens in
11 patients who had had GSD Ia or III for more than
20 years [6].
The complex case described here presented some
typical eye signs of DGS, such as retinal vascular tor-
tuosity, eyelid hooding, strabismus and astigmatism
[7]. Hypocalcemia, which may be present in DGS, is a
known cause of cataract in humans [8]; however,
there are no published reports of cataract associated
with DGS. The influence of a calcium-free environ-
ment on membrane permeability of the lens has been
extensively examined [9–11]. In vitro studies have
been concerned primarily with the short-term effect
on the lens of calcium levels so low as to be un-
physiological. Clinically, it is recognized that lens
Table 2 Lists of genes analyzed in focused exome data analyses. The HPO panels were generated using the gene-phenotype
associations in Human Phenotype Ontology project data. Other panels were constructed based on the existing gene-disease
associations
Virtual gene panel List of genes in the panel
1 gene associated with optic nerve drusen presentation MFRP
132 genes, associated with a broad set of genes
associated with cataract phenotype (HP:0000518)
ABCB6, ADAMTS10, ADAMTSL4, AGK, AGPS, AKR1E2, ALDH18A1, B3GALTL, BCOR, BFSP1,
BFSP2, CBS, CHMP4B, COL11A1, COL18A1, COL2A1, COL4A1, COL4A2, CRYAA, CRYAB,
CRYBA1, CRYBA4, CRYBB1, CRYBB2, CRYBB3, CRYGB, CRYGC, CRYGD, CRYGS, CTDP1,
CUTL1, CYP27A1, CYP51A1, DHCR7, EPG5, EPHA2, ERCC1, ERCC2, ERCC3, ERCC5, ERCC6,
ERCC8, EYA1, FAM126A, FBN1, FKRP, FKTN, FOXC1, FOXD3, FOXE3, FTL, FYCO1, FZD4,
GALK1, GALT, GCNT2, GJA1, GJA3, GJA8, GLA, GNPAT, HMX1, HSF4, JAM3, L1CAM, LARGE,
LEPREL1, LIM2, LMX1B, LRP5, LTBP2, MAF, MAN2B1, MFSD6L, MIP, MIR184, MYH9, NDP,
NF2, NHS, OCRL, OPA3, PAX6, PEX1, PEX10, PEX11β, PEX12, PEX13, PEX14, PEX16, PEX19,
PEX2, PEX26, PEX3, PEX5L, PEX6, PEX7, PITX2, PITX3, POMT1, POMT2, PVRL3, PXDN, RAB18,
RAB3GAP1, RAB3GAP2, RECQL2, RECQL4, RNLS, SC5DL, SEC23A, SIL1, SIX5, SIX6,
SLC16A12, SLC2A1, SLC33A1, SOLH, SORD, SOX2, SRD5A3, SREBF2, TBC1D20, TDRD7,
TFAP2A, TMEM114, TMEM70, VAV2, VAV3, VIM, VSX2, WFS1
255 genes in an expanded eye panel ABCA4, ABHD12, ACAD11, ADAM9, AHI1, AIPL1, ALMS1, ALX3, ALX4, ANK2, ANKRD1,
ANO5, AP3B1, ARL13B, ARL6, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BCOR,
BEST1, BLOC1S3, BLOC1S6, BMP4, C1QTNF5, C2orf71, C2ORF71, C5orf42, C8orf37,
C8ORF37, CA4, CABP4, CACNA1F, CACNA2D4, CAPN5, CC2D2A, CCDC28B, CDH23, CDH3,
CDHR1, CEP164, CEP290, CEP41, CERKL, CHM, CIB2, CLN3, CLRN1, CNGA1, CNGA3, CNGB1,
CNGB3, CNNM4, COL11A1, COL11A2, COL2A1, COL9A1, COL9A2, CRB1, CRX, CRYBA4,
CYP1B1, CYP4V2, DFNB31, DHDDS, DHODH, DTNBP1, EFEMP1, EFNB1, ELOVL4, EVC, EVC2,
EYS, FAM161A, FKRP, FKTN, FLVCR1, FOXC1, FOXE3, FRAS1, FREM1, FREM2, FSCN2, FZD4,
GNAT1, GNAT2, GNPTG, GPR143, GPR179, GPR98, GRK1, GRM6, GUCA1A, GUCA1B,
GUCY2D, HARS, HCCS, HMCN1, HPS1, HPS3, HPS4, HPS5, HPS6, IDH3B, IL11RA, IMPDH1,
IMPG2, INPP5E, INVS, IQCB1, JAG1, KCNJ13, KCNV2, KIF7, KLHL7, LARGE, LCA5, LRAT, LRIT3,
LRP5, LYST, LZTFL1, MAK, MC1R, MERTK, MFN2, MFRP, MKKS, MKS1, MSX2, MTTP, MYO7A,
MYOC, NDP, NMNAT1, NPHP1, NPHP3, NPHP4, NR2E3, NRL, NYX, OAT, OCA2, OFD1,
OPA1, OPA3, OPTN, OTX2, PANK2, PAX2, PAX6, PCDH15, PDE6A, PDE6B, PDE6C, PDE6G,
PDE6H, PDZD7, PEX1, PEX2, PEX26, PEX7, PHYH, PITPNM3, PITX2, PITX3, PLA2G5, POLR1C,
POMGNT1, POMT1, POMT2, PRCD, PROM1, PRPF3, PRPF31, PRPF6, PRPF8, PRPH2, RAB28,
RAX2, RB1, RBP3, RBP4, RD3, RDH12, RDH5, RECQL4, RGR, RGS9, RGS9BP, RHO, RIMS1,
RLBP1, ROM1, RP1, RP1L1, RP2, RP9, RPE65, RPGR, RPGRIP1, RPGRIP1L, RS1, SAG,
SDCCAG8, SEMA4A, SIX6, SLC24A1, SLC45A2, SMOC1, SNRNP200, SOX2, SPATA7, SPG7,
STRA6, TCOF1, TCTN1, TCTN2, TCTN3, TIMM8A, TIMP3, TMEM126A, TMEM138, TMEM216,
TMEM231, TMEM237, TMEM67, TOPORS, TREX1, TRIM32, TRPM1, TSPAN12, TTC21B, TTC8,
TTPA, TULP1, TWIST1, TYR, TYRP1, UNC119, USH1C, USH1G, USH2A, VAX1, VCAN, VPS13B,
VSX2, WDPCP, WFS1, ZNF423, ZNF513
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changes associated with hypocalcemia develop over a
variable timespan. In vivo, during the early stages of
hypocalcemia, the lens may employ compensating
mechanisms to overcome small permeability changes.
Delamere et al. described lens changes in hypocalce-
mic rabbits; the lenses developed posterior subcapsu-
lar punctate opacities with no cortical involvement,
but affecting most of the posterior subcapsular region
with time [12]. The pattern of development of lens
opacities was similar to that described in our case
and in human studies6. Lens changes in the patient
described here were: a) subcapsular and b) multiple,
punctate and peripheral opacities; this is in agreement
with other published findings [6, 8–12].
The etiology of ONHD is still not clear. Many studies
support Lorentzen’s theory of an irregularly dominant
inheritance pattern resulting in approximately ten times
the prevalence rate found in the general population
[13–16]. An investigation in 1999 concluded that the
primary pathology of optic disk drusen is most likely
an inherited dysplasia of the optic disk and its blood
supply, which would predispose to drusen formation
[17]. An alternative explanation for the inheritance of
optic disk drusen could be inheritance of the optic
disk size, which by itself is a risk factor for the devel-
opment of ONHD [18]. Although scleral canal size is
not an etiologic factor in the pathogenesis of ONHD,
the canal can be measured using OCT in patients
with optic nerve drusen [19]. A congenitally abnormal
disk vasculature may allow transudation of plasma
proteins which can then serve as a nidus for the
deposition of extracellular materials, facilitating the
progression of drusen [20].
Although the presence of cataract and ONHD could
be a coincidence; the case reported here might
suggest that they could have a common pathogenesis.
In fact Ringvold et al. suggest that hypocalcemic cata-
racts contain increased amounts of calcium; this is
the first report of such a finding in human specimens
[21], and it agrees with similar experimental observa-
tions from different species [22–25]. It also fits with
the observation that hypocalcemic patients may ac-
quire calcium deposits in the brain and other organs
[26]; this theory could explain the drusen in our case.
ONHD contain mucopolysaccharides, aminoacids, ribo-
nucleic and desoxyribonucleic acid, with small amounts of
iron and especially calcium [27–29].
Conclusions
The association between GSD I and cataract is known in
literature [6], instead it has not been previously reported
cases of GSD I and DGS associated with ONHD.
There are several pathogenic hypotheses concerning
both the onset of cataracts in metabolic syndromes and
the formation of ONHD. Our genetic study on the pa-
tient and her parents had the objective of verifying
whether cataract and/or ONHD had genetic causes, but
no specific causative mutation was found. However, the
etiology of the lens changes observed are in agreement
with the literature [6, 8–12], where the pathogenesis of
ONHD is still not clear.
Although in the case reported the presence of ONHD
could be a coincidence, it will be interesting in the fu-
ture: a) to assess their incidence in patients suffering
from DGS and hypocalcemic diseases to check whether
they can be caused by metabolic disorders; b) to do NGS
studies on patients with ONHD and their parents to
examine whether the drusen could be caused by muta-
tions of recessive genes not yet known.
Abbreviations
DGS: DiGeorge syndrome; G6P: Glucose-6-phosphatase; GSD: With
glycogenosis; OD: Right eye; ONHD: Optic nerve head drusen; OS: Left eye;
OU: Both eyes
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